by Clinical Neuropsychologist | Friday, October 11, 2024 | Dementia
Abstract INTRODUCTION Understanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population-based or neuropathologic comparisons have...
by Clinical Neuropsychologist | Friday, October 11, 2024 | Dementia
Abstract INTRODUCTION Recent technological advances have increased the risk that de-identified brain images could be re-identified from face imagery. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a leading source of publicly available de-identified...
by Clinical Neuropsychologist | Friday, October 11, 2024 | Dementia
Abstract INTRODUCTION This study examines the role of lifestyle factors in cognitive reserve among older adults, focusing on the moderating effect of apolipoprotein E (APOE) ε4 status. METHODS Data from 157 participants aged 45 and older from the Healthy Brain...
by Clinical Neuropsychologist | Friday, October 11, 2024 | Dementia
Abstract INTRODUCTION Microglial responses are an integral part of Alzheimer’s disease (AD) pathology and are associated with amyloid beta (Aβ) deposition. This study aimed to investigate the effects of Aβ and microglial responses on global cognitive impairment....
by Clinical Neuropsychologist | Thursday, October 10, 2024 | Dementia
Abstract INTRODUCTION We evaluated impaired odor identification and global cognition as simple, cost-effective alternatives to neuroimaging biomarkers to predict cognitive decline and dementia in the Mayo Clinic Study of Aging. METHODS Six hundred forty-seven...
